Chemokines in Type 1 Diabetes Mellitus

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Mar 4

PMID 35242125

Authors

Xiongfeng Pan

Atipatsa C Kaminga

Sanjay Kinra

Shi Wu Wen

Hongying Liu

Xinrui Tan

Aizhong Liu

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies suggested that chemokines may play an important role in the formation and mediation of immune microenvironments of patients affected by Type 1 Diabetes Mellitus (T1DM). The aim of this study was to summarise available evidence on the associations of different chemokines with T1DM.

Methods: Following PRISMA guidelines, we systematically searched in PubMed, Web of Science, Embase and Cochrane Library databases for studies on the associations of different chemokines with T1DM. The effect size of the associations were the standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs) of the chemokines concentrations, calculated as group differences between the T1DM patients and the controls. These were summarized using network meta-analysis, which was also used to rank the chemokines by surface under cumulative ranking curve (SUCRA) probabilities.

Results: A total of 32 original studies on the association of different chemokines with T1DM were identified. Fifteen different chemokine nodes were compared between 15,683 T1DM patients and 15,128 controls, and 6 different chemokine receptor nodes were compared between 463 T1DM patients and 460 controls. Circulating samples (blood, serum, and plasma) showed that concentrations of CCL5 and CXCL1 were significantly higher in the T1DM patients than in the controls (SMD of 3.13 and 1.50, respectively). On the other hand, no significant difference in chemokine receptors between T1DM and controls was observed. SUCRA probabilities showed that circulating CCL5 had the highest rank in T1DM among all the chemokines investigated.

Conclusion: The results suggest that circulating CCL5 and CXCL1 may be promising novel biomarkers of T1DM. Future research should attempt to replicate these findings in longitudinal studies and explore potential mechanisms underlying this association.

Citing Articles

Therapeutic Effects of Lavender Oil on Streptozotocin-Induced Diabetes Mellitus and Experimental Thrombosis.

But V, Rus V, Ilyes T, Gherman M, Stanescu I, Bolboaca S Antioxidants (Basel). 2025; 14(2).

PMID: 40002353 PMC: 11851820. DOI: 10.3390/antiox14020166.

The Role of Inflammation in the Pathogenesis of Diabetic Peripheral Neuropathy: New Lessons from Experimental Studies and Clinical Implications.

Panou T, Gouveri E, Popovic D, Papazoglou D, Papanas N Diabetes Ther. 2025; 16(3):371-411.

PMID: 39928224 PMC: 11868477. DOI: 10.1007/s13300-025-01699-7.

Sex-specific cytokine, chemokine, and growth factor signatures in T1D patients and progressors.

Girdhar K, Mine K, DaCosta J, Atkinson M, Ludvigsson J, Altindis E FASEB J. 2024; 38(24):e70270.

PMID: 39704278 PMC: 11660211. DOI: 10.1096/fj.202402354R.

Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications.

van Heck J, Ajie M, Joosten L, Tack C, Stienstra R Diabetes Obes Metab. 2024; 27(2):719-728.

PMID: 39562286 PMC: 11701194. DOI: 10.1111/dom.16066.

A Missing Puzzle in Preclinical Studies-Are CCR2, CCR5, and Their Ligands' Roles Similar in Obesity-Induced Hypersensitivity and Diabetic Neuropathy?-Evidence from Rodent Models and Clinical Studies.

Bober A, Mika J, Piotrowska A Int J Mol Sci. 2024; 25(20).

PMID: 39457105 PMC: 11508617. DOI: 10.3390/ijms252011323.

References

Pan X, Kaminga A, Wen S, Liu A . Chemokines in post-traumatic stress disorder: A network meta-analysis. Brain Behav Immun. 2020; 92:115-126. DOI: 10.1016/j.bbi.2020.11.033. View

Rosa J, Oliver S, Mitsuhashi M, Flores R, Pontello A, Zaldivar F . Altered kinetics of interleukin-6 and other inflammatory mediators during exercise in children with type 1 diabetes. J Investig Med. 2008; 56(4):701-13. PMC: 6190588. DOI: 10.2310/JIM.0b013e31816c0fba. View

Christen U . Chemokines as drug targets in type 1 diabetes. Endocr Metab Immune Disord Drug Targets. 2007; 7(1):7-12. DOI: 10.2174/187153007780059405. View

Gabbay M, Sato M, Duarte A, Dib S . Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin Exp Immunol. 2012; 168(1):60-7. PMC: 3390495. DOI: 10.1111/j.1365-2249.2011.04538.x. View

Michael H, Thornton S, Xie M, Tian L . Exact inference on the random-effects model for meta-analyses with few studies. Biometrics. 2018; 75(2):485-493. PMC: 7045874. DOI: 10.1111/biom.12998. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Abke S, Neumeier M, Weigert J, Wehrwein G, Eggenhofer E, Schaffler A . Adiponectin-induced secretion of interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1, CCL2) and interleukin-8 (IL-8, CXCL8) is impaired in monocytes from patients with type I diabetes. Cardiovasc Diabetol. 2006; 5:17. PMC: 1563998. DOI: 10.1186/1475-2840-5-17. View

Seidler S, Zimmermann H, Bartneck M, Trautwein C, Tacke F . Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol. 2010; 11:30. PMC: 2910032. DOI: 10.1186/1471-2172-11-30. View

Cole K, Strick C, Paradis T, Ogborne K, Loetscher M, Gladue R . Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med. 1998; 187(12):2009-21. PMC: 2212354. DOI: 10.1084/jem.187.12.2009. View

10.

Chatzigeorgiou A, Harokopos V, Mylona-Karagianni C, Tsouvalas E, Aidinis V, Kamper E . The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Ann Med. 2010; 42(6):426-38. DOI: 10.3109/07853890.2010.495951. View

11.

Antonelli A, Ferrari S, Frascerra S, Ruffilli I, Gelmini S, Minuto M . Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes. Mol Cell Endocrinol. 2011; 349(2):255-61. DOI: 10.1016/j.mce.2011.11.001. View

12.

Ellina O, Chatzigeorgiou A, Kouyanou S, Lymberi M, Mylona-Karagianni C, Tsouvalas E . Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-γ) in type 1 diabetes mellitus nephropathy. Clin Chem Lab Med. 2012; 50(1):167-74. DOI: 10.1515/cclm.2011.881. View

13.

DerSimonian R, Laird N . Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45(Pt A):139-45. PMC: 4639420. DOI: 10.1016/j.cct.2015.09.002. View

14.

Ismail N, Abd El Baky A, Ragab S, Hamed M, Abo Hashish M, Shehata A . Monocyte chemoattractant protein 1 and macrophage migration inhibitory factor in children with type 1 diabetes. J Pediatr Endocrinol Metab. 2016; 29(6):641-5. DOI: 10.1515/jpem-2015-0340. View

15.

Pellegrini S, Sordi V, Bolla A, Saita D, Ferrarese R, Canducci F . Duodenal Mucosa of Patients With Type 1 Diabetes Shows Distinctive Inflammatory Profile and Microbiota. J Clin Endocrinol Metab. 2017; 102(5):1468-1477. DOI: 10.1210/jc.2016-3222. View

16.

Lo J, Clare-Salzler M . Dendritic cell subsets and type I diabetes: focus upon DC-based therapy. Autoimmun Rev. 2006; 5(6):419-23. DOI: 10.1016/j.autrev.2005.12.001. View

17.

Pan X, Kaminga A, Liu A, Wen S, Chen J, Luo J . Chemokines in Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Front Immunol. 2020; 11:1802. PMC: 7530185. DOI: 10.3389/fimmu.2020.01802. View

18.

Pham M, Hawa M, Roden M, Schernthaner G, Pozzilli P, Buzzetti R . Increased serum concentrations of adhesion molecules but not of chemokines in patients with Type 2 diabetes compared with patients with Type 1 diabetes and latent autoimmune diabetes in adult age: action LADA 5. Diabet Med. 2011; 29(4):470-8. DOI: 10.1111/j.1464-5491.2011.03546.x. View

19.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

20.

Cetinkalp S, Felekoglu C, Karadeniz M, Boyacioglu H, Delen Y, Yildirim E . Comparison of the effects of intensive insulin treatment modalities on cardiovascular biomarkers in type 1 diabetes mellitus. Diabetes Metab Syndr. 2015; 9(3):157-62. DOI: 10.1016/j.dsx.2015.04.011. View